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The delivery of autologous bone marrow–derived cellshas developed as a revolutionary concept for repairingthe injured heart,1 and many clinical trials have beenconducted all over the world. Although there are con-
flicting reports about the beneficial effects of bone marrow cells
for myocardial repair,2 early- and middle-phase clinical trials have
not found any severe side effects of cell-based therapy. However,
its long-term safety and feasibility have not yet been established.
We report the results of more than 5 years’ follow-up of patients
treated with the intramyocardial injection of autologous bone
marrow mononuclear cells (BM-MNCs) after coronary artery by-
pass grafting (CABG).
Clinical Summary
Between November 1999 and March 2002, 8 selected patients
undergoing standard CABG were given an intramyocardial injec-
tion of BM-MNCs into the ungrafted ischemic area (Table 1). The
collection and separation of BM-MNCs was detailed previously.1
After the completion of CABG, 322  108 BM-MNCs were
injected directly, with 622 injections, into the targeted area,
where there was no indication for CABG or intervention therapy
(Figure 1). To determine the safety and feasibility of this therapy,
we monitored the patients with blood tests (white blood cell count,
hemoglobin, C-reactive protein, glutamic oxaloacetic transminase,
glutamic pyruvic transaminase, blood urea nitrogen, creatinine,
creatine phosphokinase, and creatine phosphokinase-MB isoen-
zyme) and electrocardiograms 1, 3, 7, 14, and 30 days after
treatment in the acute phase and then 3, 6, 12, 24, 36, and 60
months after treatment in the chronic phase. Furthermore, echo-
cardiography, single photon emission computed tomography myo-
cardial perfusion scintigraphy, Holter echocardiography, chest ra-
diography, and cardiac computed tomography were performed 1,
6, 12, 24, 36, and 60 months after treatment.
No postoperative complications developed in any of the
patients. Quantitative analysis showed that the mean intensity
on scintigraphy was significantly higher than that of the preop-
erative baseline in the targeted area for cell therapy 1, 12, 36,
and 60 months after treatment (72.8  8.1 at baseline, 87.1 
3.3 at 1 month, 87.7  4.0 at 12 months, 84.5  5.2 at 36
months, and 83.9  6.5 at 60 months; P .05). Furthermore,
echocardiographic or left ventricular angiographic scanning
showed obvious improvement of regional wall motion in the
targeted area in 2 patients 1 month after treatment, and these
improvements were maintained for up to 5 years.
As we1 reported previously, the serum levels of C-reactive
protein, blood urea nitrogen, creatinine, aspartate aminotransfer-
ase, glutamic pyruvic transaminase, creatine kinase, and creatine
kinase MB at the acute phase did not increase significantly com-
pared with those in patients who underwent CABG alone in our
institution during the same period. No anemia, leukocytopenia, or
any other sign of hemopoietic abnormality was found in any
patient by 1, 2, 3, and 5 years’ follow-up blood tests. A Holter
electrocardiogram showed no new-onset malignant arrhythmias
within 5 years after the intramyocardial injection of BM-MNCs,
although premature ventricular contraction was recorded 1 year (3
couplets/24 hours) and 3 years (1 couplets/24 hours) after treat-
ment in 1 patient (patient 7), who had had premature ventricular
contraction before treatment. No sign of atopic tissue formation,
including hematoma, teratogenic tumor, or bone, was detected in
the myocardium on chest radiographic, echocardiographic, or car-
diac computed tomographic scanning in any patient during the 5
years of follow-up.
Discussion
Our long-term follow-up examinations, carried out for more
than 5 years, indicated that the intramyocardial injection of
freshly collected autologous BM-MNCs had minimal, if any,
systemic or local influences. However, it is possible that some
latent adverse effects related to the cell therapy may not have
been detected because of the scheduled timing of our follow-up
examinations and their limited terms and sensitivity. Further-
more, we must investigate continuously the most disputed side
effects of BM-MNCs, which consist of heterogeneous cell
fractions, including mature blood cells and immature stem cells.
First, multiple cytokines, including some inflammatory cyto-
kines, are released from the implanted BM-MNCs.3 Some of these
BM-MNCs will die soon after implantation because of their short
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life span or the ischemic microenvironment. Thus, there is a
possibility that the injection of BM-MNCs into ischemic myocar-
dium could trigger a local and systemic inflammatory response,
which may result in myocardial edema, myocarditis, or other
myocardial damage. Fortunately, we detected no evidence of in-
flammatory response or myocardial damage after the delivery of
up to about 2  109 BM-MNCs in this clinical trial. It is unknown
whether a severe inflammatory response would be evoked by
implanting a greater number of BM-MNCs.
The second major concern relates to the possible formation
of atopic tissue in the myocardium. As the hematopoietic,
mesenchymal, and other pluripotential stem cells in BM-MNCs
can propagate and differentiate into mature blood cells, osteo-
blasts, chondrocytes, and other types of cells,4 it is possible that
a hematoma,5 teratogenic tumor, bone, or other atopic tissue
could form in the heart after the intramyocardial injection of
BM-MNCs. However, 5 years of follow-up examinations did
not reveal any evidence of mass formation, calcification, or
other abnormal signs. Moreover, unlike myoblasts, the in-
tramyocardial implantation of BM-MNCs did not trigger ma-
lignant arrhythmias in our patients, in accordance with the
findings of other early or middle-phase clinical trials.
Although further extended clinical trials are required to
confirm its effectiveness, the intramyocardial implantation of
BM-MNCs appears to be a safe and feasible treatment for
ischemic heart diseases.
Table 1. Clinical characteristics and outcomes
Patient
Age








injection Outcomes after treatment
1 67 LAD, D1, 14PL 15PD 3.0  108 5  107 6 Obvious increase of regional perfusion,
but no change of LV wall motion
2 68 LAD, OM1, OM2 14PL 5.5  108 5  107 11 No visible improvement of regional
perfusion and LV wall motion
3 59 LAD, 14PL, 4PD 15PD 5.0  108 1  108 5 Obvious increase of regional perfusion,
and 10% increase of LV ejection
fraction
4 61 LAD, OM, 4PD, 4PL D1 1.0 109 1  108 10 No visible improvement of regional
perfusion and LV wall motion
5 73 LAD, D1, 4PL, 4PD LCX 2.2 109 1  108 22 Obvious increase of regional perfusion,
but no change of LV wall motion
6 70 LAD, D1, D2 LCX 1.7  109 1  108 17 Obvious increase of regional perfusion,
and improvement of LV wall motion
7 72 LAD, RCA LCX 1.8  109 1  108 18 No visible improvement of regional
perfusion and LV wall motion
8 50 LAD, D1, 4PL LCX 1.0  109 5  107 20 Obvious increase of regional perfusion,
and improvement of LV wall motion
LAD, left anterior descending artery; D1, 1st diagonal; D2, 2nd diagonal; RCA, right coronary artery; LCX, left circumflex artery; OM, obtuse marginal branch;
PL, the posterolateral branch; PD, the posterior descending artery; LV, left ventricular.
Figure 1. Procedure used for the in-
tramyocardial injection of bone mar-
row mononuclear cells. A, Image of the
target zone of cell injection. B, The
volume was 0.1 mL per injection. Injec-
tions were spaced about 1 cm apart
and given via a 1-mL syringe and a
26-gauge needle.
Brief Communications
1348 The Journal of Thoracic and Cardiovascular Surgery ● November 2007
References
1. Li TS, Hamano K, Hirata K, Kobayashi T, Nishida M. The safety
and feasibility of the local implantation of autologous bone marrow
cells for ischemic heart disease. J Card Surg. 2003;18(Suppl 2):S69-
75.
2. Rosenzweig A. Cardiac cell therapy—mixed results from mixed cells.
N Engl J Med. 2006;355:1274-7.
3. Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Tsutsumi Y, Ozono
R, et al. Implantation of bone marrow mononuclear cells into ischemic
myocardium enhances collateral perfusion and regional function via
side supply of angioblasts, angiogenic ligands, and cytokines. Circula-
tion 2001;104:1046-52.
4. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD,
Ortiz-Gonzalez XR, et al. Pluripotency of mesenchymal stem cells
derived from adult marrow. Nature. 2002;418:41-9.
5. Kawamoto A, Iwasaki H, Kusano K, Murayama T, Oyamada A, Silver
M, et al. CD34-positive cells exhibit increased potency and safety for
therapeutic neovascularization after myocardial infarction compared
with total mononuclear cells. Circulation. 2006;114:2163-9.
Periaortic glue application may prevent fatal aortic rupture in
nonoperable patients with acute type A aortic dissection
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Acute type A aortic dissection is a condition requiringemergency surgery. However, surgical intervention iscontroversial in concomitant stroke. We report anovel approach that prevented fatal aortic rupture in a
patient with acute type A dissection with major stroke for whom
the surgical cure was intentionally delayed.
Clinical Summary
A 65-year-old woman was hospitalized for right hemiplegia and
aphasia rapidly complicated by a comatose state. Initial evaluation
revealed temporal ischemic stroke and acute type A aortic dissec-
tion (Figure 1, A and B). It was decided to delay surgery. Circu-
latory shock developed owing to cardiac tamponade. It was then
decided to evacuate the pericardial effusion through a median
sternotomy and try to limit the risk of rupture by external gluing of
the aorta. Inspection did not show any active bleeding. Manipula-
tion of the aorta was avoided. Gelatin-resorcine-formaldehyde
(GRF) glue was applied externally all around the ascending aorta,
so that the intrapericardial segment of the aorta was no longer
visible. After placement of chest tubes, the chest was closed and
the patient transferred to the intensive care unit.
Neurologic recovery was satisfactory in the following weeks,
with complete regression of hemiplegia and partial recovery from
aphasia. One week after the initial surgical intervention, a com-
puted tomographic (CT) scan had revealed moderate periaortic
hematoma (Figure 2, A). Two weeks later, a suprasternal mass
developed. Repeat CT scan showed a large periaortic hematoma
extending to the sternum (Figure 2, B). The patient underwent
emergency surgery for an aortic false aneurysm. Sternotomy was
performed under femoro–femoral bypass and deep hypothermic
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Figure 1. A, Chest CT scan showing
type A aortic dissection. B, Left tempo-
ral ischemic stroke was present on
admission.
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